RenaZorb is a small molecule commercialized by Unicycive Therapeutics, with a leading Phase III program in Hyperphosphatemia In Chronic Kidney Disease. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RenaZorb’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for RenaZorb is expected to reach an annual total of $308 mn by 2026 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RenaZorb Overview

RenaZorb (SPI-014) is under development for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) and chronic kidney disease (CKD). The drug candidate is administered orally as a tablet. It is a second-generation lanthanum-based compound (lanthanum dioxycarbonate) targeting phosphate ions. The drug candidate is developed based on nanoparticle technology.

Unicycive Therapeutics Overview

Unicycive Therapeutics is a biotechnology company that develops novel treatments across multiple therapeutic areas. The company’s pipeline program include Renazor targeting hyperphosphatemia; UNI-494 for the treatment of acute kidney injury; and others. Unicycive Therapeutics is headquartered in Los Altos, California, the US.

The company reported revenues of (US Dollars) US$1 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$18.1 million in FY2022, compared to an operating loss of US$9 million in FY2021. The net loss of the company was US$18.1 million in FY2022, compared to a net loss of US$10 million in FY2021.

For a complete picture of RenaZorb’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.